Estados financieros detallados de Gossamer Bio, Inc. (GOSS): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 99.6%, margen operativo -311.7%, margen neto -235.0%.
Al precio actual de $10.96, GOSS presenta beneficios negativos (P/E no significativo) y un ROE del 108.75%. La capitalización bursátil es de $67M.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $114.7M | $48.5M |
| Coste de Ventas | 0 | 0 | $297000 | $3.1M | $4.3M | 0 | 0 | 0 | 0 | $1.0M |
| Beneficio Bruto | 0 | 0 | -$297000 | -$3.1M | -$4.3M | 0 | 0 | 0 | $114.7M | $47.5M |
| I+D | 0 | $891000 | $55.3M | $143.4M | $158.0M | $170.3M | $170.9M | $135.3M | $138.5M | $174.1M |
| Generales y Administrativos | $83000 | $262000 | $44.1M | $39.1M | $48.3M | $45.8M | $47.6M | $38.5M | $36.1M | $37.6M |
| Gastos Operativos | $83000 | $1.2M | $99.3M | $182.5M | $206.3M | $216.1M | $218.6M | $183.8M | $174.6M | $210.7M |
| Beneficio Operativo | -$83000 | -$6.7M | -$149.0M | -$186.1M | -$210.6M | -$216.1M | -$218.6M | -$183.8M | -$59.9M | -$163.3M |
| EBITDA | -$83000 | -$6.7M | -$149.0M | -$179.4M | -$226.4M | -$209.4M | -$211.1M | -$161.9M | -$40.0M | -$158.5M |
| Gastos por Intereses | 0 | $118000 | $12000 | 0 | $12.7M | $19.4M | $13.9M | $13.5M | $11.5M | $11.0M |
| Beneficio Antes de Impuestos | -$83000 | -$6.8M | -$147.0M | -$180.3M | -$243.4M | -$234.0M | -$229.4M | -$179.8M | -$55.6M | -$170.5M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $893000 | -$88000 |
| Beneficio Neto | -$83000 | -$6.8M | -$147.0M | -$180.8M | -$243.4M | -$234.0M | -$229.4M | -$179.8M | -$56.5M | -$170.4M |
| BPA | $-0.72 | $-59.13 | $-1807.49 | $-263.51 | $-284.17 | $-250.13 | $-216.97 | $-94.26 | $-19.99 | $-59.64 |
| BPA Diluido | $-0.72 | $-59.13 | $-1807.49 | $-263.51 | $-284.17 | $-250.13 | $-216.97 | $-94.26 | $-19.99 | $-59.64 |
| Acciones en Circulación (Diluidas) | $114511 | $114511 | $81311 | $684252 | $856378 | $935544 | $1.1M | $1.9M | $2.8M | $2.9M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | $13.3M | $13.8M | $17.0M | $9.2M |
| Beneficio Bruto | $13.3M | $13.8M | $16.7M | $9.2M |
| Beneficio Operativo | -$49.1M | -$46.0M | -$44.9M | -$26.1M |
| EBITDA | -$45.5M | -$44.3M | -$43.7M | -$71.5M |
| Beneficio Neto | -$48.2M | -$47.2M | -$46.7M | $16.9M |
| BPA | $-16.92 | $-16.68 | $-15.94 | $4.22 |
| BPA Diluido | $-16.92 | $-16.68 | $-15.94 | $-6.12 |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $60000 | $315000 | $105.2M | $135.0M | $486.1M | $183.4M | $112.0M | $32.1M | $46.1M | $37.7M |
| Inversiones a Corto | 0 | 0 | $123.4M | $266.7M | $26.6M | $141.8M | $143.7M | $264.3M | $248.4M | $99.2M |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $5.3M | $12.5M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $60000 | $445000 | $232.0M | $409.3M | $522.3M | $331.8M | $261.9M | $306.5M | $309.9M | $167.6M |
| Inmovilizado Material | 0 | 0 | $3.2M | $15.7M | $16.1M | $10.8M | $9.9M | $4.8M | $5.1M | $4.2M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $60000 | $445000 | $239.4M | $426.6M | $539.4M | $343.7M | $272.4M | $311.9M | $315.3M | $172.2M |
| Cuentas por Pagar | $40000 | $97000 | $2.2M | $956000 | $7.5M | $3.2M | $1.5M | $5.5M | $2.3M | $6.0M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | $11.6M | $11.6M | 0 | 0 |
| Pasivos Corrientes | $143000 | $1.3M | $20.4M | $36.9M | $38.6M | $39.9M | $49.2M | $51.6M | $45.0M | $63.4M |
| Deuda a Largo | $40000 | $6.0M | 0 | $28.5M | $172.4M | $179.1M | $207.7M | $197.4M | $197.5M | $198.5M |
| Pasivos Totales | $183000 | $7.3M | $359.5M | $74.1M | $218.7M | $222.2M | $260.4M | $249.1M | $285.8M | $295.0M |
| Reservas | -$123000 | -$6.9M | -$153.9M | -$334.2M | -$577.5M | -$811.5M | -$1.03B | -$1.21B | -$1.27B | -$1.44B |
| Patrimonio Neto | -$123000 | -$6.9M | -$120.1M | $352.5M | $320.7M | $121.5M | $12.1M | $62.8M | $29.5M | -$122.8M |
| Deuda Total | $40000 | $6.0M | 0 | $39.5M | $183.7M | $185.2M | $225.7M | $212.5M | $202.9M | $202.9M |
| Deuda Neta | -$20000 | $5.7M | -$228.7M | -$362.2M | -$328.9M | -$140.0M | -$29.9M | -$84.0M | -$91.6M | $66.0M |
| Capital Circulante | -$83000 | -$821000 | $211.6M | $372.4M | $483.7M | $291.9M | $212.7M | $254.9M | $264.9M | $104.2M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $8.9M | $37.7M | $41.0M | $41.1M |
| Activos Totales | $208.8M | $172.2M | $128.9M | $76.9M |
| Pasivos Totales | $291.2M | $295.0M | $290.4M | $170.9M |
| Patrimonio Neto | -$82.3M | -$122.8M | -$161.5M | -$94.0M |
| Deuda Total | $202.9M | $202.9M | $202.9M | $39.1M |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$83000 | -$6.8M | -$147.0M | -$180.3M | -$243.4M | -$234.0M | -$229.4M | -$179.8M | -$56.5M | -$170.4M |
| Amortizaciones | 0 | 0 | $297000 | $3.1M | $4.3M | $5.2M | $4.4M | $4.4M | $4.2M | $1.0M |
| Compensación en Acciones | 0 | $32000 | $30.9M | $20.8M | $38.7M | $32.0M | $42.6M | $28.5M | $20.6M | $10.6M |
| Cambio en Capital Circulante | $103000 | $994000 | $15.0M | $10.1M | -$3.1M | $774000 | -$4.5M | -$14.8M | $39.5M | -$13.6M |
| Flujo de Caja Operativo | $20000 | -$5.7M | -$51.0M | -$144.8M | -$176.4M | -$188.9M | -$187.0M | -$159.2M | -$3.5M | -$171.3M |
| Inversiones (CapEx) | 0 | 0 | -$21.2M | -$6.6M | -$24.9M | -$1.6M | -$475000 | 0 | 0 | -$79000 |
| Adquisiciones | 0 | 0 | -$17.7M | 0 | $23.4M | 0 | -$65000 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $629000 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | $20000 | -$5.7M | -$72.3M | -$151.4M | -$201.2M | -$190.5M | -$187.5M | -$159.2M | -$3.5M | -$171.3M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$36.2M | -$48.3M | -$38.7M | -$39.4M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$36.2M | -$48.3M | -$38.7M | -$39.4M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $2.7M | $2.9M | $6.3M | $2.5M |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | | | | | | | | | -57.7% |
| Crecimiento Beneficio Neto (anual) | | -8057.8% | -2070.6% | -23.0% | -34.6% | +3.8% | +2.0% | +21.6% | +68.6% | -201.4% |
| Crecimiento BPA (anual) | | -8112.5% | -2956.8% | +85.4% | -7.8% | +12.0% | +13.3% | +56.6% | +78.8% | -198.3% |
| Cambio en Acciones (anual) | | +0.0% | -29.0% | +741.5% | +25.2% | +9.2% | +13.0% | +80.5% | +48.2% | +1.0% |
| Crecimiento FCF (anual) | | -28825.0% | -1157.7% | -109.5% | -32.9% | +5.3% | +1.6% | +15.1% | +97.8% | -4840.7% |
| Margen Bruto | | | | | | | | | 100.0% | 97.9% |
| Margen Operativo | | | | | | | | | -52.2% | -336.8% |
| Margen EBITDA | | | | | | | | | -34.8% | -326.9% |
| Margen Neto | | | | | | | | | -49.3% | -351.5% |
| Margen FCF | | | | | | | | | -3.0% | -353.5% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -1.6% | 0.1% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $0.17 | $-50.17 | $-888.63 | $-221.26 | $-234.99 | $-203.64 | $-177.36 | $-83.43 | $-1.23 | $-59.98 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $114511 | $114511 | $81311 | $684252 | $856378 | $935544 | $1.1M | $1.9M | $2.8M | $2.9M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | 108.75% |
| Rentabilidad sobre capital invertido | 670.05% |
| Rentabilidad sobre activos | -162.91% |
| Margen bruto | 99.56% |
| Margen operativo | -311.70% |
| Margen neto | -235.00% |
Salud financiera
| Deuda / Patrimonio | -0.42 |
| Ratio corriente | 0.53 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -1993.33 | -24.27 | -0.79 | -4.75 | -2.72 | -3.62 | -0.80 | -0.77 | -3.62 | -4.16 |
| P/VC | -1336.15 | -23.95 | -0.97 | 2.43 | 2.07 | 6.97 | 15.20 | 2.22 | 6.94 | -5.77 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.78 | 14.62 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 97.9% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -52.2% | -336.8% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -49.3% | -351.5% |